GlassScriptPhysician profile
Michelle Denise White
NPI 1225329147
$10,962.64
in general payments reported to CMS, 2019-2025
36 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $7,341 · 2021: $350 · 2022: $363 · 2023: $576 · 2024: $350 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,517 · Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,517.44 |
| Food and Beverage | $1,099.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,448.22 | 2020-2025 | |
| Abbvie INC. | $332.05 | 2019-2025 | |
| Daiichi Sankyo INC. | $301.99 | 2019-2023 | Injectafer |
| Myriad Women'S Health, INC. | $256.91 | 2023 | Myrisk |
| Astellas Pharma US INC | $196.98 | 2020-2024 | Veozah, Izervay |
| Optumhealth Care Solutions, LLC | $172.17 | 2023-2025 | Vivify Health Care Team Portal 001, Eitan Medical, Vivify Health Care Team Portal |
| Therapeuticsmd, INC. | $113.21 | 2019-2021 | |
| Hologic Sales and Service, LLC | $95.61 | 2021-2025 | Aptima, Novasure, Acessa Provu System |
| Coopersurgical, INC. | $94.38 | 2019-2024 | Paragard T 380a |
| Exeltis, USA INC. | $93.10 | 2020-2024 | Slynd |
| Caldera Medical, INC | $92.96 | 2024 | Desara |
| Bayer Healthcare Pharmaceuticals INC. | $91.08 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $80.30 | 2021-2023 | |
| Organon LLC | $64.26 | 2022-2025 | Jada System |
| Pfizer INC. | $57.46 | 2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $44.47 | 2020-2023 | Watchman Flx |
| Evofem Biosciences, INC. | $43.08 | 2023 | Phexxi |
| Allergan, INC. | $40.04 | 2019 | |
| Biogen, INC. | $29.75 | 2025 | Zurzuvae |
| Ethicon US, LLC | $29.65 | 2020-2024 | Ethicon, Vistaseal, Stratafix |
| Avion Pharmaceuticals | $28.80 | 2021 | |
| Mylan Pharmaceuticals INC. | $27.64 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $26.38 | 2023 | Myfembree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.78 | 2020 | |
| Novo Nordisk INC | $19.60 | 2024 | Wegovy |
| Scynexis, INC. | $19.51 | 2022 | |
| Shield Therapeutics INC | $18.96 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $18.42 | 2020 | |
| Meditrina | $15.17 | 2022 | |
| Baxter Healthcare | $14.92 | 2023 | Tisseel |
| Currax Pharmaceuticals LLC | $13.73 | 2020 | |
| Roche Diagnostics Corporation | $13.36 | 2019 | |
| Merck Sharp & Dohme LLC | $13.19 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.36 | 2019 | |
| Aspira Women'S Health INC | $10.36 | 2024 | Ova1 |
| Channel Medsystems, INC. | $9.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.